3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding

Journal of Medicinal Chemistry

Volumn 47, Issue 13, 2004, Pages 3367-3380

  Pevarello, Paolo ^a   Brasca, Maria Gabriella ^a   Amici, Raffaella ^a   Orsini, Paolo ^a   Traquandi, Gabriella ^a   Corti, Luca ^a   Piutti, Claudia ^a   Sansonna, Pietro ^a   Villa, Manuela ^a   Pierce, Betsy S ^e   Pulici, Maurizio ^a   Giordano, Patrizia ^a   Martina, Katia ^a   Fritzen, Edward L ^e   Nugent, Richard A ^e   Casale, Elena ^a   Cameron, Alexander ^a   Ciomei, Marina ^b   Roletto, Fulvia ^c   Isacchi, Antonella ^c   Fogliatto, GianPaolo ^c   Pesenti, Enrico ^b   Pastori, Wilma ^b   Marsiglio, Aurelio ^b   Leach, Karen L ^e   Clare, Paula M ^e   Fiorentini, Francesco ^d   Varasi, Mario ^a   Vulpetti, Anna ^a   Warpehoski, Martha A ^e   more..

^a Chemistry Department   (Italy)

^b Pharmacology Department   (Italy)

^c Biology Department   (Italy)

^d Global Drug Metabolism Department   (Italy)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPYRAZOLE INHIBITOR; ANTINEOPLASTIC AGENT; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; FLAVOPIRIDOL; N (5 CYCLOPROPYL 1H PYRAZOL 3 YL) 2 (2 NAPHTHYL)ACETAMIDE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PNU 292137; PYRAZOLE DERIVATIVE; ROSCOVITINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; RAT; TOXICITY; X RAY CRYSTALLOGRAPHY; XENOGRAFT;

ACETAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CDC2-CDC28 KINASES; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; CYCLIN A; CYCLIN-DEPENDENT KINASE 2; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 2942522534     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031145u     Document Type: Article

References (42)

1. Hatakeyama, M.; Weinberg, R. A. The role of RB in cell cycle control. Prog. Cell Cycle Res. 1995, 1, 9-19.
2. Morgan, D. O.; Fisher, R. P.; Espinoza, F. H.; Farrell, A.; Nourse, J.; Chamberlin, H.; Jin, P. Control of eukaryotic cell cycle progression by phosphorylation of cyclin-dependent kinases. Cancer J. Sci. Am. 1998, 4 (Suppl. 1), S77-S83.
3. Sherr, C. J. Cancer cell cycles. Science 1996, 274, 1672-1677.
4. Malumbres, M.; Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 2001, 1 (3), 222-231.
5. Tsutsui, T.; Hesabi, B.; Moons, D. S.; Pandolfi, P. P.; Hansel, K. S.; Koff, A.; Kiyokawa, H. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol. Cell. Biol. 1999, 19 (10), 7011-70199.
6. Dynlacht, B. D.; Flores, O.; Lees, J. A.; Harlow, E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes Genes Dev. 1994, 8 (15), 1772-1786.
7. Xu, M.; Sheppard, K. A.; Peng, C. Y.; Yee, A. S.; Piwnica-Worms, H. Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation Mol. Cell. Biol. 1995, 14 (12), 8420-8431.
8. Pagano, M.; Pepperkok, R.; Verde, F.; Ansorge, W.; Draetta, G. Cyclin A is required at two points in the human cell cycle EMBO J. 1992, 11 (3), 961-971.
9. Donnellan, R.; Chetty, R. Cyclin E in human cancers. FASEB J. 1999, 13 (8), 773-780.
10. Tokuyama, Y.; Horn, H. F.; Kawamura, K.; Tarapore, P.; Fukasawa, K. Specific phosphorylation of nucleophosmin on Thr-(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication. J. Biol. Chem. 2001, 276 (24), 21529-21537. Meraldi, P.; Lukas, J.; Fry, A. M.; Bartek, J.; Nigg, E. A. Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A Nat. Cell Biol. 1999, 1 (2), 88-93.
11. Tokuyama, Y.; Horn, H. F.; Kawamura, K.; Tarapore, P.; Fukasawa, K. Specific phosphorylation of nucleophosmin on Thr-(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication. J. Biol. Chem. 2001, 276 (24), 21529-21537. Meraldi, P.; Lukas, J.; Fry, A. M.; Bartek, J.; Nigg, E. A. Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A Nat. Cell Biol. 1999, 1 (2), 88-93.
12. Hall, C.; Nelson, D. M.; Ye, X.; Baker, K.; DeCaprio, J. A.; Seeholzer, S.; Lipinski, M.; Adams, P. D. HIRA, the human homologue of yeast Hir1p and Hir2p, is a novel cyclin-cdk2 substrate whose expression blocks S-phase progression Mol. Cell. Biol. 2001, 21 (5), 1854-1865.
13. Zhao, J.; Kennedy, B. K.; Lawrence, B. D.; Barbie, D. A.; Matera, A. G.; Fletcher, J. A.; Harlow, E. NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev. 2000, 14 (18), 2283-2297.
14. Okuda, M.; Horn, H. F.; Tarapore, P.; Tokuyama, Y.; Smulian, A. G.; Chan, P. K.; Knudsen, E. S.; Hofmann, I. A.; Snyder, J. D.; Bove, K. E.; Fukasawa, K. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication Cell 2000, 103 (1), 127-140.
15. Pagano, M.; Pepperkok, R.; Lukas, J.; Baldin, V.; Ansorge, W.; Bartek, J.; Draetta, G. Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts. J. Cell Biol. 1993, 121 (1), 101-111. Girard, F.; Strausfeld, U.; Fernandez, A.; Lamb, N. J. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 1991, 67 (6), 1169-1179.
16. Pagano, M.; Pepperkok, R.; Lukas, J.; Baldin, V.; Ansorge, W.; Bartek, J.; Draetta, G. Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts. J. Cell Biol. 1993, 121 (1), 101-111. Girard, F.; Strausfeld, U.; Fernandez, A.; Lamb, N. J. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 1991, 67 (6), 1169-1179.
17. Kitagawa, M.; Higashi, H.; Suzuki-Takahashi, I.; Segawa, K.; Hanks, S. K.; Taya, Y.; Nishimura, S.; Okuyama, A. Phosphorylation of E2F-1 by cyclin A-cdk2. Oncogene 1995, 10 (2), 229-236.
18. Krek, W.; Xu, G.; Livingston, D. M. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell 1995, 83 (7), 1149-1158. Xu, M.; Sheppard, K. A.; Peng, C. Y.; Yee, A. S.; Piwnica-Worms, H. Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol. Cell. Biol. 1994, 14 (12), 8420-8431.
19. Krek, W.; Xu, G.; Livingston, D. M. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell 1995, 83 (7), 1149-1158. Xu, M.; Sheppard, K. A.; Peng, C. Y.; Yee, A. S.; Piwnica-Worms, H. Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol. Cell. Biol. 1994, 14 (12), 8420-8431.
20. DeGregori, J.; Leone, G.; Miron, A.; Jakoi, L.; Nevins, J. R. Distinct roles for E2F proteins in cell growth control and apoptosis Proc. Natl. Acad. Sci. U.S.A. 1997, 94 (14), 7245-7250.
21. Chen, Y. N.; Sharma, S. K.; Ramsey, T. M.; Jiang, L.; Martin, M. S.; Baker, K.; Adams, P. D.; Bair, K. W.; Kaelin, W. G., Jr. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (8), 4325-4329.
22. Tsihlias, J.; Kapusta, L.; Slingerland, J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 1999, 50, 401-423.
23. Lloyd, R. V.; Erickson, L. A.; Jin, L.; Kulig, E.; Qian, X.; Cheville, J. C.; Scheithauer, B. W. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am. J. Pathol. 1999, 154 (2), 313-323.
24. Tetsu, O.; McCormick, F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003, 3 (3), 233-245.
25. Senderowicz, A. M. Small-molecule cyclin-dependent kinase modulators Oncogene 2003, 22 (42), 6609-6620.
26. Zhai, S.; Senderowicz, A. M.; Sausville, E. A.; Figg, W. D. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann. Pharmacother. 2002, 36, 905-911.
27. McClue, S. J.; Blake, D.; Clarke, R.; Cowan, A.; Cummings, L.; Fischer, P. M.; MacKenzie, M.; Melville, J.; Stewart, K.; Wang, S.; Zhelev, N.; Zheleva, D.; Lane, D. P. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 2002, 102 (5), 463-468.
28. Misra, R. N.; Xiao, H.-Y.; Kim, K. S.; Lu, S.; Han, W.-]C.; Rawlins, D. B.; Shan, W.; Ahmed, S. Z.; Qian, L.; Chen, B.-C.; Zhao, R.; Bednarz, M. S.; Bursuker, I.; Kellar, K. A.; Mulheron, J. G.; Batorsky, R. K.; Kamath, A.; Humphreys, W. G.; Marathe, P.; Hunt, J. T.; Pavletich, N. P.; Kimball, S. D.; Webster, K. R. BMS-387032: A selective cdk2 inhibitor with potent antitumor activity. Abstracts of Papers, 225th National Meeting of the American Chemical Society, New Orleans, LA, March 23-27, 2003.
29. Pevarello, P.; Orsini, P.; Traquandi, G.; Varasi, M.; Fritzen, E. L.; Warpehoski, M. A.; Pierce, B. S.; Brasca, M. G.3(5)-Acylaminopyrazole derivatives, process for their preparation and their use as antitumor agents. International Patent WO 01/12189.
30. Seelen, W.; Schäfer, M.; Ernst, A. Selective ring N-protection of aminopyrazoles. Tetrahedron Lett. 2003, 44, 4491-4493.
31. De Azevedo, W. F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S. H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 1997, 243 (1-2), 518-26.
32. Pavletich, N. P. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J. Mol. Biol. 1999, 287 (5), 821-828.
33. Ling, V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 1997, 40 (Suppl.), S3-S8.
34. For a general discussion, see the following. Baguley, B. C.; Hicks, K. O.; Wilson, W. R. Tumor cell cultures in drug development. In Anticancer Drug Development; Baguley, B. C., Kerr, D. J., Eds.; Academic Press: San Diego, CA, 2002; pp 269-284.
35. Isacchi, A. Manuscript in preparation.
36. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
37. Jeffrey, P. D.; Russo, A. A.; Polyak, K.; Gibbs, E.; Hurwitz, J.; Massague, J.; Pavletich, N. P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995, 376, 313-320.
38. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods in Enzymology; Academic Press: New York, 1997; Vol. 276.
39. Brünger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P. ; Grosse-Kunstleve, R. W. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr., Sect. D 1998, 54, 905-921.
40. Rosenblatt, J.; De Bondt, H.; Jancarik, J.; Morgan, D. O.; Kim, S. H. Purification and crystallization of human cyclin-dependent kinase 2. J. Mol. Biol. 1993, 230 (4), 1317-1319.
41. Lawrie, A. M.; Noble, M. E. M.; Tunnah, P.; Brown, N. R.; Johnson, L. N. ; Endicott, J. A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat. Struct. Biol. 1997, 4, 796-801.
42. Kleywegt, G. J.; Jones, T. A. Phi/psi-chology: Ramachandran revisited. Structure 1996, 4, 1395-1400.